Table 3.
Summarizes effects on recurrence and progression in the recent meta-analyses.
| Studies | N° pts | Drugs | Recurrence or Progression | New Primary Tumors |
|---|---|---|---|---|
| Augustin M [41] | 1756 | Secukinumab | No recurrence or progression. | NR |
| Lebwohl M [42] | 10,685 | Secukinumab | No recurrence or progression. | EAIR of malignancy was 0.85/100 PTY, corresponding to 204 patients per 23 908 PY |
| Blauvelt A [43] | 1721 | Guselkumab | No recurrence or progression. | EAIR of malignancy was 0.74/100 PY, corresponding to 53 patients per 7117 PY |
| [44] | 112 studies including 2,053,932 patients | Patients receiving biologic therapy and non-biologic therapy | No recurrence or progression. | No increase in cancer was seen among patients with psoriasis treated with biologic agents |
| Gupta A [45] | 31 studies, 24,328 persons | Patients receiving biologic therapy and non-biologic therapy | Rates of cancer recurrence were similar among individuals not on immunosuppression, receiving an anti-TNF, immunomodulators, or combination immunosuppression. Patients receiving ustekinumab and vedolizumab had lower rates of cancer. | NR |
| Smith SD [46] | 17 studies, including 6892 patients | Ixekizumab | 55 patients developed NMSC, 1 melanoma, 1 dermatofibrosarcoma protuberans | |
| Gottlieb A 2022 [47] | 8891 | Secukinumab | EAIR/100PY 224 (PsO) EAIR/100PY 159.2 (PsA) EAIR/100PY 125.5 (AS) |
NR |
| Jung JM [48] | 191,678 | TNF-α inhibitor/IL12/23 inhibitor | SIR, 1.12; 95% (CI 1.09–1.14). TNF-α inhibitor (aHR 1.41; 95% CI 1.01–1.97). IL-12/23 inhibitor (aHR, 0.57; 95% CI 0.37–0.87). |
NR |
| Gargiulo L 2023 [49] | 606 | Brodalumab | The log-rank test and Cox regression did not detect any differences in drug survival regarding BMI classes, comorbidities, involvement of difficult-to-treat areas, and previous exposure to biologics | 1 prostate cancer 1 breast cancer, (after 16 weeks of treatment) they both stopped brodalumab to undergo surgery |
| Hellgren K [50] | 55,850 | TNF-α inhibitor | HR for solid cancer overall was 1.0 (0.9–1.2) for TNFi-exposed vs biologics-naïve PsA | NR |
Abbreviations: EAIR Exposed-adjusted incidence rates; PY patient year; NR not reported; SIR standardized incidence rates; CI confidence interval; aHR adjusted hazard ratio; PsO Psoriasis; PsA psoriatic arthritis; AS ankylosing spondylitis.